title: Association between FAS 1377G>A polymorphism and breast cancer susceptibility: a meta-analysis.
abstract: Published studies on the association between FAS 1377G>A polymorphism and breast cancer susceptibility were inconclusive. To derive a more precise assessment of the association, a meta-analysis of published studies was performed. PubMed, Embase, and Web of Science were searched for eligible studies on the association between FAS 1377G>A polymorphism and breast cancer susceptibility. Five studies with a total of 2,905 cases and 3,090 controls were included into the meta-analysis. Overall, FAS 1377G>A polymorphism was significantly associated with increased susceptibility to breast cancer (for AA versus GG: odds ratio (OR) = 1.39, 95% confidence interval (95% CI) 1.12-1.72, P = 0.003; for AA/GA versus GG: OR = 1.18, 95% CI 1.06-1.32, P = 0.004; for AA versus GG/GA: OR = 1.28, 95% CI 1.05-1.56, P = 0.015). Subgroup analysis by ethnicity found that FAS 1377G>A polymorphism was significantly associated with increased susceptibility to breast cancer in Asians (for AA versus GG: OR = 1.48, 95% CI 1.16-1.89, P = 0.001; for AA/GA versus GG: OR = 1.24, 95% CI 1.06-1.46, P = 0.008; for AA versus GG/GA: OR = 1.35, 95% CI 1.08-1.69, P = 0.008), but the association was not found in Caucasians. Therefore, the findings of the meta-analysis suggest that FAS 1377G>A polymorphism is significantly associated with increased susceptibility to breast cancer in Asians.
authors: Department of Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China, kaidrsheny@hotmail.com.
authors: Kai
authors: K
authors: Li
authors: Wusheng
authors: W
authors: Li
authors: Huawei
authors: H
authors: Zou
authors: Li
authors: L
authors: Zhao
mesh_terms: D000483:Alleles; D001943:Breast Neoplasms / Q000208:ethnology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D019014:fas Receptor / Q000235:genetics*
chemical_list: D019014:fas Receptor
references: Lancet Oncol. 2011 Oct;12(11):1053-61
references: 21621462
references: J Natl Cancer Inst. 2004 Oct 6;96(19):1478-9; author reply 1479
references: 15467038
references: Hum Genet. 2009 May;125(4):431-5
references: 19225810
references: Br J Cancer. 2013 Jun 25;108(12):2610-22
references: 23756864
references: J Clin Oncol. 2011 Nov 20;29(33):4381-6
references: 21969512
references: Tumour Biol. 2013 Oct;34(5):2753-7
references: 23765759
references: Expert Opin Ther Targets. 2011 Oct;15(10):1143-5
references: 21736533
references: Lancet. 2011 Nov 19;378(9805):1804-11
references: 22098853
references: Nat Rev Clin Oncol. 2011 Aug 02;8(11):669-76
references: 21808267
references: Cell. 2011 Mar 18;144(6):926-39
references: 21414484
references: Carcinogenesis. 2007 Dec;28(12):2548-51
references: 17962219
references: Oncol Lett. 2012 Mar;3(3):625-628
references: 22740964
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Nat Cell Biol. 2011 Mar;13(3):184-90
references: 21364565
references: Nat Immunol. 2009 Apr;10(4):348-55
references: 19295631
references: Lancet. 2011 Nov 19;378(9805):1812-23
references: 22098854
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Carcinogenesis. 2007 May;28(5):1067-73
references: 17183065
references: Lancet. 2011 Oct 22;378(9801):1461-84
references: 21924486
references: Carcinogenesis. 2009 Mar;30(3):487-93
references: 19168581
references: J Clin Oncol. 2011 Dec 1;29(34):4505-9
references: 22042950
references: PLoS One. 2013;8(1):e53075
references: 23326385
references: Am J Epidemiol. 2013 Jun 15;177(12):1317-25
references: 23729685
references: Hum Immunol. 2012 Sep;73(9):932-8
references: 22732091
references: CMAJ. 2011 Dec 13;183(18):2109-16
references: 22065359